CEO Jasbir Seehra outlined the company’s development priorities and partnership plans during a presentation at Oppenheimer’s 36th Annual Healthcare Life Sciences conference, highlighting plans to init ...
Capricor Therapeutics’ stock has soared by more than 370% after a pivotal trial of its Duchenne muscular dystrophy (DMD) cell therapy candidate met its endpoints. The Phase III HOPE-3 trial ...
Taking advantage of investor interest in its Duchenne muscular dystrophy drug, Capricor Therapeutics secured an upsized US$150m late on Thursday from an overnight stock sale. Following an earlier wall ...
Detailed price information for Precision Biosciences Inc (DTIL-Q) from The Globe and Mail including charting and trades.
Phase 1/2a ELIMINATE-B trial for PBGENE-HBV ongoing across multiple dosing cohorts; Data updates expected at medical conferences in 2026 PBGENE-DMD expecting IND clearance in Q1 2026 for Phase 1/2 ...
Duchenne muscular dystrophy (DMD) is a neuromuscular disorder that results from mutations in the DMD gene. Gene therapies for DMD change genetic material in a person’s body to treat this condition.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results